First-in-Human trial tests re-engineered immune cells to fight cancer
NCT ID NCT06088472
Summary
This is an early-stage safety study testing a new personalized cell therapy called GT101. It involves collecting a patient's own immune cells from a tumor, growing large numbers of them in a lab, and then infusing them back into the patient to fight their cancer. The main goal is to see if this treatment is safe for adults with advanced or returning solid tumors that have spread or come back after other treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS, ADULT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Affiliated Hospital of Xuzhou Medical University
RECRUITINGXuzhou, Jiangsu, 221000, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.